Skip to main content
PVLA
NASDAQ Life Sciences

Palvella Posts $24.6M Q3 Loss, $236.7M Cash Ahead of Feb 2027 PDUFA

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$153.3
Mkt Cap
$2.338B
52W Low
$71.55
52W High
$163.75
52W Position info
114% above low
Off High info
6.4% below high
Rel. Volume info
1.8× avg
Market data snapshot near publication time

PVLA has more than doubled off its 52-week low of $71.55 on elevated volume (1.8× avg).

Summary

Palvella burned $24.6 million in Q3, up from $11.3 million a year ago, as R&D jumped to $10.8 million and G&A nearly quadrupled to $11.9 million on launch and public-company costs, producing a loss of $1.70 per share. It ended September with $236.7 million in cash and short-term investments, down modestly from $250.6 million at mid-year, which funds the planned standalone U.S. commercial launch in the first half of 2027 if QTORIN rapamycin is approved. The FDA accepted the NDA and granted Priority Review with a February 28, 2027 PDUFA date, the central binary for the stock. Pipeline timing held: Phase 3 cutaneous venous malformation trial starts in Q4 2026, Phase 2 DSAP trial starts in Q4 2026, and two additional programs will be announced by year-end. The company also named James R. Treat, M.D. Chief Medical Officer effective December 21, 2026.

At the time of this announcement, PVLA was trading at $153.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $71.55 to $163.75. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

PVLA - Latest Insights

PVLA
Nov 19, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $147.00
Real-time Price: $142.85 info
Change: -$4.15 (-3%) info
Market Cap: $2.088B info
PVLA
Nov 05, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $153.30
Real-time Price: $142.85 info
Change: -$10.45 (-7%) info
Market Cap: $2.088B info
PVLA
Oct 28, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $127.00
Real-time Price: $142.85 info
Change: +$15.85 (+12%) info
Market Cap: $2.088B info
PVLA
Oct 28, 2026, 7:30 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $134.99
Real-time Price: $142.85 info
Change: +$7.86 (+6%) info
Market Cap: $2.088B info
PVLA
Aug 31, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $150.34
Real-time Price: $142.85 info
Change: -$7.49 (-5%) info
Market Cap: $2.088B info